Presently, an emerging disease (COVID-19) has
been spreading across the world due to coronavirus (SARS-CoV2). For treatment
of SARS-CoV2 infection, currently hydroxychloroquine has been suggested by
researchers, but it has not been found enough effective against this virus. The
present study based on in silico approaches was designed to enhance the
therapeutic activities of hydroxychloroquine by using curcumin as an adjunct
drug against SARS-CoV2 receptor proteins: main-protease and S1 receptor binding
domain (RBD). The webserver (ANCHOR) showed the higher protein stability for
both receptors with disordered score (<0.5). The molecular
docking analysis revealed that the binding energy (-24.58 kcal/mol) of
hydroxychloroquine was higher than curcumin (-20.47 kcal/mol) for receptor
main-protease, whereas binding energy of curcumin (<a>-38.84</a>
kcal/mol) had greater than hydroxychloroquine<a> (-35.87</a>
kcal/mol) in case of S1 receptor binding domain. Therefore, this study
suggested that the curcumin could be used as combination therapy along with
hydroxychloroquine for disrupting the stability of SARS-CoV2 receptor proteins
Concurrent expression of erbB receptor proteins in human meningiomas
